Migraine Pipeline, Clinical Trials, Emerging Therapies and FDA Approvals 2023 (Updated)

DelveInsight’s, “Migraine Pipeline Insight 2023” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Migraine pipeline landscape. It covers the Migraine pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Migraine pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Migraine Pipeline Report

• DelveInsight’s Migraine pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Migraine treatment.
• The leading companies working in the Migraine Market include Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics, and others.
• Promising Migraine Pipeline Therapies in the various stages of development include Lasmiditan, Sumatriptan, ABP-450, Eptinezumab, AMG334, Frovatriptan 2.5 mg, and others.
• September 2023: Amgen announced a study of phase 3 clinical trials for Erenumab Dose 1. This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to
• September 2023: Pfizer announced a study of phase 3 clinical trials for Rimegepant 75mg Orally Disintegrating Tablets (ODT). This trial is to evaluate the long-term safety and tolerability of Rimegepant 75mg ODT in Chinese subjects with migraine.

Request a sample and discover the recent advances in Migraine Treatment Drugs @ Migraine Pipeline Report

In the Migraine pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Migraine collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Migraine Overview

Migraine is a neurological pain condition that affects millions of people. It is the most common neurological disease that has significant effects on the brain and consequently on behaviors associated with repeated migraine attacks. The stress of migraine is associated with premigraine, intermigraine, and postmigraine processes.

Find out more about Migraine Therapeutics Assessment @ Migraine Preclinical and Discovery Stage Products

Migraine Emerging Drugs Profile

• AXS-07: Axsome Therapeutics
• STS-101: Satsuma Pharmaceuticals
• Zavegepant: Biohaven Pharmaceuticals
• TNX1900: Tonix Pharmaceuticals

Migraine Pipeline Therapeutics Assessment

There are approx. 30+ key companies which are developing the Migraine therapies. The Migraine companies which have their Migraine drug candidates in the most advanced stage, i.e. phase III include, Novartis.

Learn more about the emerging Migraine Pipeline Therapies @ Migraine Clinical Trials Assessment

Scope of the Migraine Pipeline Report

• Coverage- Global
• Migraine Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Migraine Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Migraine Companies- Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics, and others.
• Migraine Pipeline Therapies- Lasmiditan, Sumatriptan, ABP-450, Eptinezumab, AMG334, Frovatriptan 2.5 mg, and others.

Dive deep into rich insights for new drugs for Migraine Treatment, Visit @ Migraine Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Migraine: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Migraine– DelveInsight’s Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. AXS-07: Axsome Therapeutics
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase III)
11. STS-101: Satsuma Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. TNX1900: Tonix Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Migraine Key Companies
21. Migraine Key Products
22. Migraine - Unmet Needs
23. Migraine - Market Drivers and Barriers
24. Migraine - Future Perspectives and Conclusion
25. Migraine Analyst Views
26. Migraine Key Companies
27. Appendix

For further information on the Migraine Pipeline therapeutics, reach out to Migraine Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Migraine Pipeline, Clinical Trials, Emerging Therapies and FDA Approvals 2023 (Updated)